Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis

Annals of Oncology

Volumn 26, Issue 2, 2015, Pages 428-435

  Barrera, L ^a,b   Montes Servin E ^a   Barrera, A ^c   Ramirez Tirado L A ^d   Salinas parra, F ^a   Banales Mendez J L ^a,e   Sandoval Rios M ^f   Arrieta, O'scar ^b,d  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO TECNOLÓGICO AUTÓNOMO DE MÉXICO   (Mexico)

^d INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^e INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^f Division of Natural Sciences Regional Center for Teacher Development and Educational Research (CRFDIES) of Sonora   (Mexico)

Author keywords

Biomarkers; Cytokines; Data mining analysis; Non small cell lung cancer; Prognosis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HEMOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 27; INTERLEUKIN 29; INTERLEUKIN 31; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGE; ARTICLE; BIOASSAY; BODY MASS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CYTOMETRIC BEAD ARRAY ASSAY; DATA MINING; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FUNCTIONAL STATUS; HUMAN; HYPOALBUMINEMIA; HYPOREXIA; LEUKOCYTE COUNT; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SMOKING; SURVIVAL TIME; AGED; BLOOD; CLASSIFICATION; CLUSTER ANALYSIS; IMMUNOLOGY; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CLUSTER ANALYSIS; CYTOKINES; DATA MINING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84925341188     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu549     Document Type: Article

References (26)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Arrieta O´, Nu´ñez-Valencia C, Reynoso-Erazo L et al. Health-related quality of life in patients with lung cancer: alidation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire. Lung Cancer 2012; 77: 205-211.
3. Borish LC, Steinke JW. 2. Cytokines and chemokines. J Allergy Clin Immunol 2003; 111: S460-S475.
4. Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancerrelated inflammation. Cytokine 2008; 43: 374-379.
5. Shiels MS, Pfeiffer RM, Hildesheim A et al. Circulating inflammation markers and prospective risk for lung cancer. J Natl Cancer Inst 2013; 105(24): 1871-1880.
6. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 2860-2867.
7. Frantz S, Vincent KA, Feron O, Kelly RA. Innate immunity and angiogenesis. Circ Res 2005; 96: 15-26.
8. Costantini S, Capone F, Guerriero E, Castello G. An approach for understanding the inflammation and cancer relationship. Immunol Lett 2009; 126: 91-92.
9. Bodelon C, Polley MY, Kemp TJ et al. Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer. Ann Oncol 2013; 24: 2073-2079.
10. Ahmed K, Al Emran A, Jesmin T et al. Early detection of lung cancer risk using data mining. Asian Pac J Cancer Prev 2013; 14: 595-598.
11. Witten IH, Frank E, Hall MA. Data Mining: Practical Machine Learning Tools and Techniques. 3rd edition. Burlington, MA: Morgan Kaufmann, 2011. Ch. 4 ( pp. 99-107, 138-141), Ch. 5 (pp. 152-154, 163-180), Ch. 6 ( pp. 192-203, 287-289).
12. Bower JE, Lamkin DM. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav Immun 2013; 30 (suppl): S48-S57.
13. Songu¨r N, Kuru B, Kalkan F et al. Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori 2004; 90: 196-200.
14. Dinarello CA. Historical insights into cytokines. Eur J Immunol 2007; 1(suppl): S34-S45.
15. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and Cancer. Cell 2010; 140: 883-899.
16. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-78.
17. Mantovani A, Pierotti MA. Cancer and inflammation: a complex relationship. Cancer Lett 2008; 267(2): 180-181.
18. Sa´nchez-Lara K, Turcott JG, Jua´rez-Herna´ndez E et al. Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial. Clin Nutr 2014; 33: 1017-1023.
19. Sa´nchez-Lara K, Turcott JG, Jua´rez E et al. Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study. Nutr Cancer 2012; 64: 526-534.
20. Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1-10.
21. Witte K, Witte E, Sabat R, Wolk K. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev 2010; 21: 237-251.
22. Fujie H, Tanaka T, Tagawa M et al. Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer. Cancer Sci 2011; 102: 1977-1990.
23. Zitzmann K, Brand S, Baehs S et al. Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun 2006; 344: 1334-1341.
24. Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 2011; 22: 83-89.
25. Chan SH, Perussia B, Gupta JW et al. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 1991; 173: 869-879.
26. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro-and antiinflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011; 1813(5): 878-888.